Literature DB >> 1635810

Current status of Duchenne muscular dystrophy.

S T Iannaccone1.   

Abstract

Duchenne muscular dystrophy is the second most common lethal genetic disorder in humans. With the advent of molecular genetic technology, the definition of this disease has been modified to include an abnormality of dystrophin in muscle--a dystrophinopathy. Accurate genetic counseling is possible using methods of deletion detection and linkage analysis. Treatment of this type of muscular dystrophy may soon mean the routine use of steroids and later include direct injection of an artificial gene for dystrophin.

Entities:  

Mesh:

Year:  1992        PMID: 1635810     DOI: 10.1016/s0031-3955(16)38379-1

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  4 in total

1.  The anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy.

Authors:  V Jensen
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

2.  Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors.

Authors:  B Cai; M J Spencer; G Nakamura; L Tseng-Ong; J G Tidball
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Modulation by prednisolone of calcium handling in skeletal muscle cells.

Authors:  L Metzinger; A C Passaquin; W J Leijendekker; P Poindron; U T Rüegg
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Dexamethasone stimulates store-operated calcium entry and protein degradation in cultured L6 myotubes through a phospholipase A(2)-dependent mechanism.

Authors:  Kiyoshi Itagaki; Michael Menconi; Bozena Antoniu; Qin Zhang; Patricia Gonnella; David Soybel; Carl Hauser; Per-Olof Hasselgren
Journal:  Am J Physiol Cell Physiol       Date:  2010-01-27       Impact factor: 4.249

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.